Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 20/20 | 0.97 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.60 |
| ▸ | PDE1A | P54750 | 8/20 | 0.60 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.60 |
| ▸ | PDE1C | Q14123 | 8/20 | 0.60 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.60 |
| ▸ | PDE5A | O76074 | 4/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3952082 | 0.98 | PDE7A (1.00) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3028910 | 0.98 | PDE7A (1.00) | PDE7APDE4DPDE1APDE1BPDE1C | |
| Acetic Acid SCHEMBL3953446 | 0.92 | PDE7A (0.87) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL20641787 | 0.87 | PDE7A (0.75) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL5529818 | 0.86 | PDE7A (1.00) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3022180 | 0.81 | PDE7A (0.70) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3025481 | 0.79 | PDE7A (0.66) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL8115990 | 0.78 | PDE7A (0.97) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL3952384 | 0.77 | PDE7A (1.00) | PDE7APDE4DPDE1APDE1BPDE1C | |
| SCHEMBL8245267 | 0.77 | PDE7A (1.00) | PDE7APDE4DPDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216823-A1 | Spirocyclic Derivatives | PFIZER INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216823-A1 | Spirocyclic Derivatives | PFIZER INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216823-A1 | Spirocyclic Derivatives | PFIZER INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2008142550-A9 | SPIROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS PDE7 INHIBITORS | PFIZER LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
| US-7507742-B2 | Spirocyclic derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507742-B2 | Spirocyclic derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507742-B2 | Spirocyclic derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2008142550-A2 | SPIROCYCLIC DERIVATIVES | PFIZER LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
| US-20070129388-A1 | Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid | PFIZER, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129388-A1 | Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid | PFIZER, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129388-A1 | Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid | PFIZER, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007063391-A2 | SPIROCYCLIC QUINAZOLINE DERIVATIVES AS PDE7 INHIBITORS | PFIZER LIMITED (GB) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129388-A1 | Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid | PDE7A, PDE7B, PDE3A | PDE7A 1/4885PDE4D 26/4885PDE1A 9/4885 |
| US-20100216823-A1 | Spirocyclic Derivatives | PDE7B, PDE6B, PDE7A | PDE7A 3/4885PDE4D 22/4885PDE1A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.